JP2021514398A5 - - Google Patents
Info
- Publication number
- JP2021514398A5 JP2021514398A5 JP2020566546A JP2020566546A JP2021514398A5 JP 2021514398 A5 JP2021514398 A5 JP 2021514398A5 JP 2020566546 A JP2020566546 A JP 2020566546A JP 2020566546 A JP2020566546 A JP 2020566546A JP 2021514398 A5 JP2021514398 A5 JP 2021514398A5
- Authority
- JP
- Japan
- Prior art keywords
- carbon atoms
- group
- combination pharmaceutical
- egfr inhibitor
- pharmaceutical preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862632798P | 2018-02-20 | 2018-02-20 | |
| US62/632,798 | 2018-02-20 | ||
| PCT/US2019/018770 WO2019164945A1 (en) | 2018-02-20 | 2019-02-20 | Pharmaceutical combinations of egfr inhibitors and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021514398A JP2021514398A (ja) | 2021-06-10 |
| JP2021514398A5 true JP2021514398A5 (enExample) | 2022-02-25 |
Family
ID=67686991
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020566546A Pending JP2021514398A (ja) | 2018-02-20 | 2019-02-20 | Ｅｇｆｒ阻害剤の組合せ医薬製剤およびその使用法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20210077469A1 (enExample) |
| EP (1) | EP3755330A4 (enExample) |
| JP (1) | JP2021514398A (enExample) |
| AU (1) | AU2019225803A1 (enExample) |
| CA (1) | CA3088972A1 (enExample) |
| WO (1) | WO2019164945A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113993589A (zh) * | 2019-06-21 | 2022-01-28 | 豪夫迈·罗氏有限公司 | 新egfr抑制剂 |
| WO2020257607A1 (en) * | 2019-06-21 | 2020-12-24 | Dana-Farber Cancer Institute, Inc. | Allosteric egfr inhibitors and methods of use thereof |
| IL326872A (en) | 2019-11-11 | 2026-04-01 | Dana Farber Cancer Inst Inc | EGFR allosteric inhibitors and methods of using them |
| CN111592535B (zh) * | 2020-06-22 | 2021-07-20 | 通化师范学院 | 一种抗egfr突变的抑制剂eai045的制备方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5386350B2 (ja) * | 2006-05-31 | 2014-01-15 | タケダ カリフォルニア インコーポレイテッド | グルコキナーゼ活性剤としての、インダゾールおよびイソインドール誘導体 |
| WO2012129562A2 (en) * | 2011-03-24 | 2012-09-27 | The Scripps Research Institute | Compounds and methods for inducing chondrogenesis |
| MY161925A (en) * | 2011-07-27 | 2017-05-15 | Astrazeneca Ab | 2 - (2, 4, 5 - substituted -anilino) pyrimidine derivatives as egfr modulators useful for treating cancer |
| CN105315259B (zh) * | 2014-07-29 | 2018-03-09 | 上海艾力斯医药科技有限公司 | 吡啶胺基嘧啶衍生物、其制备方法及应用 |
| CA2987914C (en) * | 2015-06-30 | 2022-09-13 | Dana-Farber Cancer Institute, Inc. | Inhibitors of egfr and methods of use thereof |
| EP3892272B1 (en) * | 2016-04-22 | 2024-07-24 | Dana-Farber Cancer Institute, Inc. | Bifunctional molecules for degradation of egfr and methods of use |
-
2019
- 2019-02-20 CA CA3088972A patent/CA3088972A1/en active Pending
- 2019-02-20 AU AU2019225803A patent/AU2019225803A1/en not_active Abandoned
- 2019-02-20 EP EP19758033.5A patent/EP3755330A4/en not_active Withdrawn
- 2019-02-20 WO PCT/US2019/018770 patent/WO2019164945A1/en not_active Ceased
- 2019-02-20 US US16/971,021 patent/US20210077469A1/en not_active Abandoned
- 2019-02-20 JP JP2020566546A patent/JP2021514398A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025508703A5 (enExample) | ||
| JP2021514011A5 (enExample) | ||
| AU2013213260B2 (en) | Imidazopyrrolidinone compounds | |
| JP2024532735A5 (enExample) | ||
| JP5579715B2 (ja) | ｃｄｋ阻害剤および抗悪性腫瘍剤を含む治療用組合せ | |
| JP2003500404A5 (enExample) | ||
| AR087336A1 (es) | Compuestos de 2-(2,4,5-anilino sustituido)pirimidina | |
| RU2014105624A (ru) | Соединения индазола, способ их применения и фармацевтическая композиция | |
| SI3106463T1 (en) | Compounds of substituted pyrazolo (1,5-) pyrimidine as inhibitors of TRK kinase | |
| RU2004106783A (ru) | Производные 4-амино-6-фенилпирроло[2, 3] пиримидина | |
| JP2019519586A5 (enExample) | ||
| RU2015148189A (ru) | ПРОИЗВОДНЫЕ 2-АМИДОПИРИДО[4, 3-d]ПИРИМИДИН-5-ОНА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ WEE-1 | |
| JP2007519694A5 (enExample) | ||
| JP2009536620A5 (enExample) | ||
| RU2008144806A (ru) | 4-анилинохинолин-3-карбоксамиды в качестве ингибиторов csf-1r киназы | |
| MY189118A (en) | Pyrazolo[1,5-a]pyrazin-4-yl derivatives | |
| JP2011507854A5 (enExample) | ||
| RU2002129557A (ru) | Производные 8-хинолинксантина и 8-изохинолинксантина в качестве ингибиторов фосфоэстеразы pde5 | |
| ES2807785T3 (es) | Compuestos de heteroarilamina bicíclicos como inhibidores de pi3k | |
| RU2009119181A (ru) | Гетероциклические соединения и их применение в качестве ингибиторов гликогенсинтаза-киназы-3 | |
| JP2017501983A5 (enExample) | ||
| JP2018522861A5 (enExample) | ||
| JP2021518379A5 (enExample) | ||
| RU2009103300A (ru) | Производные 2-бензоилимидазопиридинов, их получение и их применение в терапии | |
| RU2012133686A (ru) | Арилсульфамидные производные пиридинопиридинонов, их получение и их применение в терапии |